» Articles » PMID: 24202447

MicroRNA in Human Glioma

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2013 Nov 9
PMID 24202447
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Glioma represents a serious health problem worldwide. Despite advances in surgery, radiotherapy, chemotherapy, and targeting therapy, the disease remains one of the most lethal malignancies in humans, and new approaches to improvement of the efficacy of anti-glioma treatments are urgently needed. Thus, new therapeutic targets and tools should be developed based on a better understanding of the molecular pathogenesis of glioma. In this context, microRNAs (miRNAs), a class of small, non-coding RNAs, play a pivotal role in the development of the malignant phenotype of glioma cells, including cell survival, proliferation, differentiation, tumor angiogenesis, and stem cell generation. This review will discuss the biological functions of miRNAs in human glioma and their implications in improving clinical diagnosis, prediction of prognosis, and anti-glioma therapy.

Citing Articles

Screening miRNAs to Hinder the Tumorigenesis of Renal Clear Cell Carcinoma Associated with KDR Expression.

Kaviyaprabha R, R K, Miji T, Tv M, Suseela R, R S Curr Cancer Drug Targets. 2024; 25(2):183-203.

PMID: 39289946 DOI: 10.2174/0115680096321287240826065718.


MicroRNA as a potential diagnostic and prognostic biomarker in brain gliomas: a systematic review and meta-analysis.

Hasani F, Masrour M, Jazi K, Ahmadi P, Hosseini S, Lu V Front Neurol. 2024; 15:1357321.

PMID: 38487328 PMC: 10937740. DOI: 10.3389/fneur.2024.1357321.


The evidence for repurposing anti-epileptic drugs to target cancer.

Aroosa M, Malik J, Ahmed S, Bender O, Ahemad N, Anwar S Mol Biol Rep. 2023; 50(9):7667-7680.

PMID: 37418080 PMC: 10460753. DOI: 10.1007/s11033-023-08568-1.


Role of DNMTs in the Brain.

Bora Yildiz C, Zimmer-Bensch G Adv Exp Med Biol. 2022; 1389:363-394.

PMID: 36350518 DOI: 10.1007/978-3-031-11454-0_15.


MicroRNAs as prognostic markers and therapeutic targets in gliomas.

Sufianov A, Begliarzade S, Ilyasova T, Liang Y, Beylerli O Noncoding RNA Res. 2022; 7(3):171-177.

PMID: 35846075 PMC: 9271693. DOI: 10.1016/j.ncrna.2022.07.001.


References
1.
Lee H, Bier A, Cazacu S, Finniss S, Xiang C, Twito H . MicroRNA-145 is downregulated in glial tumors and regulates glioma cell migration by targeting connective tissue growth factor. PLoS One. 2013; 8(2):e54652. PMC: 3563647. DOI: 10.1371/journal.pone.0054652. View

2.
Pickering M, Stadler B, Kowalik T . miR-17 and miR-20a temper an E2F1-induced G1 checkpoint to regulate cell cycle progression. Oncogene. 2008; 28(1):140-5. PMC: 2768269. DOI: 10.1038/onc.2008.372. View

3.
Bao S, Wu Q, McLendon R, Hao Y, Shi Q, Hjelmeland A . Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120):756-60. DOI: 10.1038/nature05236. View

4.
Wu D, Wang Y, Fan L, Luo H, Han B, Sun L . MicroRNA-7 regulates glioblastoma cell invasion via targeting focal adhesion kinase expression. Chin Med J (Engl). 2011; 124(17):2616-21. View

5.
Kefas B, Comeau L, Erdle N, Montgomery E, Amos S, Purow B . Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells. Neuro Oncol. 2010; 12(11):1102-12. PMC: 3098027. DOI: 10.1093/neuonc/noq080. View